Clinical trials: Persistent Thrombocytopenia
Immune Thrombocytopenia (ITP)
National Multicenter Retrospective Real-World Study on the Treatment Status of Newly Diagnosed and Persistent Primary Immune Thrombocytopenia (ITP) Patients
This study is a nationwide, multicenter, retrospective, real-world, non-interventional (observational) investigation. It retrospectively collects data on treatment modalities and therapeutic responses in patients with newly…
- Trial name
- NCT07268898
- Volunteers
- 500 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Primary Immune Thrombocytopenia (ITP)
TPO-RAs Combining Anti-CD 20 Monoclonal Antibody Versus TPO-RAs in the Management of Pediatric Primary Immune Thrombocytopenia (ITP)
This multicenter randomized, open-label study aim to compare the efficacy and safety of TPO-RAs combining anti-CD 20 monoclonal antibody with TPO-RAs in China pediatric ITP patients .This study will be conducted in persistent or…
- Trial name
- NCT05718856
- Testing
- TPO-RAs, TPO-RAs combining anti-CD 20 monoclonal antibody
- Where
- China
- Volunteers
- 166 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Hepatitis C Infection, Thrombocytopenia
Romiplostim in Treating Hepatitis C-Infected Patients With Thrombocytopenia
RATIONALE: Romiplostim may cause the body to make platelets. PURPOSE: This randomized phase II trial is studying how well romiplostim works in treating hepatitis C-infected patients with thrombocytopenia.
- Trial name
- NCT01153919
- Testing
- romiplostim, ribavirin, PEG-interferon alfa-2a
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- University of Southern California
Healthy, Primary Immune Thrombocytopenia
A First in HumanTrial to Evaluate The Safety, Tolerability, And Pharmacokinetics Of PF-06755347
This phase 1 single ascending dose study will provide a first in human assessment of safety and tolerability of PF-06755347 in healthy adult males as well as adult males and females with Immune Thrombocytopenia (ITP).
- Conditions
- Healthy, Primary Immune Thrombocytopenia, Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
- Trial name
- NCT03275740
- Testing
- PF-06755347 intravenous healthy participant, PF-06755347 subcutaneous healthy participant, PF-06755347 subcutaneous ITP
- Where
- 6 sites in United States, Belgium and 3 more
- Volunteers
- 58 people, healthy volunteers welcome
- Sponsor
- Pfizer
Persistent Isolated Chemotherapy-Induced Thrombocytopenia, Chemotherapy-Induced Thrombocytopenia
Romiplostim N01 Plus ATRA for Persistent Isolated Chemotherapy-Induced Thrombocytopenia After Complete Remission of Gastrointestinal Solid Tumors
This is a prospective, randomized, open-label, active-controlled study to evaluate the efficacy and safety of Romiplostim N01 plus all-trans retinoic acid (ATRA) compared with Romiplostim N01 alone in adults with persistent…
- Conditions
- Persistent Isolated Chemotherapy-Induced Thrombocytopenia, Chemotherapy-Induced Thrombocytopenia, Gastrointestinal Neoplasms, Pancreatic Cancer
- Trial name
- N01-A-PICIT-GI (NCT07586813)
- Testing
- Romiplostim N01, All-trans retinoic acid
- Where
- China
- Volunteers
- 220 people
- Sponsor
- Peking University People's Hospital
Persistent Thrombocytopenia Following Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)
Using ROMIPLOSTINE for Persistent Thrombocytopenia With Transfusion-dependent Patients Who Received Allogeneic Hematopoietic Stem Cell
This is a Phase I/II multicenter study which aims to assess the toxicity profile of Romiplostim in patients with transfusion-dependent thrombocytopenia after allogeneic HSCT.
- Trial name
- AGRAH003 (NCT01980030)
- Testing
- Romiplostim
- Where
- France
- Volunteers
- 24 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Immune Thrombocytopenic Purpura
Open Label Study of R788 in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP)
The primary objective of this study was to assess the long term safety of fostamatinib in subjects with persistent/chronic ITP
- Trial name
- NCT02077192
- Testing
- Fostamatinib Disodium
- Where
- 55 sites in United States, Australia and 13 more
- Volunteers
- 123 people
- Sponsor
- Rigel Pharmaceuticals
Gastrointestinal Cancer, Gastrointestinal Neoplasms
Avatrombopag vs. Placebo for CIT in GI Malignancies
The purpose of this study is to compare the efficacy of two study drugs, Avatrobopag versus placebo, to treat persistent Chemotherapy-Induced Thrombocytopenia (CIT) in patients with gastrointestinal (GI) malignancies receiving…
- Conditions
- Gastrointestinal Cancer, Gastrointestinal Neoplasms, Chemotherapy-Induced Thrombocytopenia
- Trial name
- ACT-GI (NCT05772546)
- Testing
- Avatrombopag
- Where
- 4 sites in United States
- Volunteers
- 49 people
- Sponsor
- Hanny Al-Samkari, MD
Primary Immune Thrombocytopenia (ITP)
Efficacy and Safety of Subcutaneous Belimumab or Placebo in Addition of Rituximab in Persistent or Chronic Immune Thrombocytopenia
Primary immune thrombocytopenia (ITP) is an autoimmune disease mainly mediated by autoreactive B cells and the presence of pathogenic anti-platelet auto-antibodies that enhance platelet destruction and impair platelet production.
- Trial name
- RITUX-PLUS 2 (NCT05338190)
- Testing
- Combination of Rituximab with subcutaneous belimumab
- Where
- France
- Volunteers
- 132 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Immune Thrombocytopenia (ITP)
A Study to Investigate the Efficacy and Safety of Lusutrombopag (S-888711) Tablets Administered to Adults With Immune Thrombocytopenia (ITP)
The primary objective of this study was to assess the efficacy of 3 dose levels of lusutrombopag (0.5 mg, 0.75 mg, and 1.0 mg) and placebo on platelet count.
- Trial name
- NCT01054443
- Testing
- Lusutrombopag
- Where
- 19 sites in United States
- Volunteers
- 20 people
- Sponsor
- Shionogi
Immune Thrombocytopenic Purpura
A Efficacy and Safety Study of Fostamatinib in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP)
The purpose of this study is to determine whether fostamatinib is safe and effective in the treatment of persistent/chronic Immune Thrombocytopenic Purpura (ITP).
- Trial name
- FIT (NCT02076412)
- Testing
- Fostamatinib Disodium
- Where
- 35 sites in United States, Austria and 7 more
- Volunteers
- 74 people
- Sponsor
- Rigel Pharmaceuticals
Immune Thrombocytopenia, Platelet Disorder
Safety and Efficacy of Eltrombopag at Escalated Doses
Study rationale is based on the data that in previous clinical studies of eltrombopag in ITP there are some patients who have been reported as non responders at the maximal approved dose of 75 mg daily.
- Trial name
- NCT01880047
- Testing
- Eltrombopag
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Weill Medical College of Cornell University
Immune Thrombocytopenia
PRTX-100-202 Open-Label, Dose Escalation Study in Adult Patients With ITP
Pre-clinical and clinical evaluations show that PRTX- 100 has biological activity that may lead to improved platelet levels where these are decreased due to immunological pathologies and that PRTX-100 has an acceptable safety…
- Trial name
- NCT02401061
- Testing
- PRTX-100
- Where
- 11 sites in United States, United Kingdom
- Volunteers
- 13 people
- Sponsor
- Protalex, Inc.
Immune Thrombocytopenia
Rituximab and Dexamethasone Followed by Mycophenolate Mofetil or Placebo in Patients With Immune Thrombocytopenia
The investigators will attempt to further increase the cure rate of ITP with medical therapy by providing maintenance therapy with Mycophenolate mofetil (MMF) to persistent/chronic ITP patients after treating them with induction…
- Trial name
- NCT02649504
- Testing
- Rituximab, Dexamethasone, Mycophenolate mofetil
- Sponsor
- Weill Medical College of Cornell University
Persistent or Chronic ITP
Rate of Prolonged Response After Stopping Thrombopoietin-receptor Agonists Treatment in ITP
Thrombopoietin-receptor agonists (Tpo-RAs) have profoundly changed the management of ITP. However, today, there are no international recommendations concerning the long-term use of these costly, potentially pro-thrombotic agents…
- Trial name
- STOP-AGO (NCT03119974)
- Testing
- Tpo-RA discontinuation
- Where
- France
- Volunteers
- 48 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Immune Thrombocytopenic Purpura, Helicobacter Pylori
H. Pylori Eradication for Moderate ITP
The purpose of this study is to determine the efficacy of H. pylori eradication for the treatment of chronic or persistent immune thrombocytopenic purpura (ITP) patients with moderate thrombocytopenia.
- Conditions
- Immune Thrombocytopenic Purpura, Helicobacter Pylori, Immune Thrombocytopenia
- Trial name
- NCT03177629
- Testing
- treatment : H. pylori eradication
- Where
- South Korea
- Volunteers
- 54 people
- Sponsor
- Seoul National University Hospital
Idiopathic Thrombocytopenic Purpura, Immune Thrombocytopenia
Lusutrombopag in the Treatment of Immune Thrombocytopenia (ITP)
This exploratory study is to investigate the efficacy, safety and tolerability of Lusutrombopag in the treatment of primary immune thrombocytopenia in Chinese patients who have failed first-line therapy
- Trial name
- NCT06287567
- Testing
- Lusutrombopag Oral Tablet
- Where
- China
- Volunteers
- 17 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Primary Immune Thrombocytopenia
A Study to Investigate the Long-term Safety, Tolerability, and Efficacy of Rozanolixizumab in Study Participants With Persistent or Chronic Primary Immune Thrombocytopenia (ITP)
The purpose of this study is to assess the long-term safety, tolerability and clinical efficacy of treatment with rozanolixizumab.
- Trial name
- myOpportunITy3 (NCT04596995)
- Testing
- Rozanolixizumab
- Where
- 27 sites in United States, China and 12 more
- Volunteers
- 43 people
- Sponsor
- UCB Biopharma SRL
Primary Immune Thrombocytopenia
A Study to Assess the Efficacy, Safety, and Tolerability of Rozanolixizumab in Adult Study Participants With Persistent or Chronic Primary Immune Thrombocytopenia (ITP)
The purpose of this study is to demonstrate the clinical efficacy of rozanolixizumab in maintenance treatment and assess safety and tolerability of rozanolixizumab in adult study participants with primary immune thrombocytopenia…
- Trial name
- myOpportunITy2 (NCT04224688)
- Testing
- Rozanolixizumab
- Where
- 29 sites in United States, Bulgaria and 9 more
- Volunteers
- 30 people
- Sponsor
- UCB Biopharma SRL